Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1529571

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1529571

Biosimilars Market, By Drug Class, By Therapy Type, By Distribution Channel, By Geography

PUBLISHED:
PAGES: 231 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Global biosimilars market is estimated to be valued at USD 36.01 Bn in 2024 and is expected to reach USD 114.02 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 17.9% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 36.01 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 17.90% 2031 Value Projection: US$ 114.02 Bn
Figure. Biosimilars Market Share (%), By Region 2024
Biosimilars Market - IMG1

Global biosimilars market growth is driven by rising healthcare costs worldwide and the expiration of blockbuster biologics patents. Biosimilars provide affordable treatment options for chronic diseases such as cancer, diabetes, and autoimmune disorders. These offer significant cost savings as compared to reference biologics. For example, Filgrastim's biosimilar Zarzio was launched at a 15% lower price compared to original biologic Neupogen. Regulatory approvals for biosimilars have also increased in major markets like the U.S, EU, and Japan following clear guidelines, thus, easing market entry. This has attracted many emerging players to the large and lucrative biosimilars market.

Market Dynamics:

Global biosimilars market growth is driven by factors like rising chronic disease prevalence rates worldwide coupled with limited healthcare budgets. This has boosted demand for lower-cost biosimilar alternatives to biologics. Many blockbusters biologic drugs are expected to lose patent protection over the forecast period 2018-2026, thus, offering potential for biosimilar entrants. For instance, infliximab and adalimumab are among the highest revenue earning biologics that faced biosimilar competition by 2023. Regulatory approvals and product launches, along with marketing expansion activities by major players can drive the market growth.

Key Features of the Study:

  • This report provides in-depth analysis of the global biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global biosimilars market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Novartis, Pfizer, Teva Pharmaceuticals, Celltrion, Biocon, Amgen, Samsung Biologics, Stada Arzneimittel AG.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biosimilars market.

Detailed Segmentation-

  • By Drug Class
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
  • By Therapy Type
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Amgen Inc.
    • Pfizer Inc.
    • Samsung Bioepis Co., Ltd.
    • Sandoz International GmbH
    • Celltrion Healthcare Co., Ltd.
    • Biocon Limited
    • Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Fresenius Kabi AG
    • Merck & Co., Inc.
    • Biogen Idec Inc
    • Coherus BioSciences
    • Stada Arzneimittel AG
Product Code: CMI750

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Therapy Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Biosimilars Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Biosimilars Market, By Drug Class, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Recombinant Human Growth Hormone
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Granulocyte Colony-Stimulating Factor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Insulin
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Anticoagulants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Fusion Proteins Erythropoietin
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Monoclonal Antibodies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Follitropin
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Biosimilars Market, By Therapy Type, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Oncology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Immunology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Hematology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Hormone Therapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Metabolic Disorders
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Biosimilars Market, By Distribution Channel, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Specialty Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Biosimilars Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Amgen Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Samsung Bioepis Co., Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sandoz International GmbH
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Celltrion Healthcare Co., Ltd.
    • Biocon Limited
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Fresenius Kabi AG
    • Merck & Co., Inc.
    • Biogen Idec Inc
    • Coherus BioSciences
    • Stada Arzneimittel AG

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!